☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
ESMO 2021
Biocad Presents Results of BCD-021 (biosimilar, bevacizumab) in P-III Study for the Treatment of NSCLC at ESMO 2021
October 27, 2021
Exelixis Presents Results of Cabometyx (cabozantinib) in P-III COSMIC-311 Trial for the Treatment of Radioactive Iodine-Refractory...
September 22, 2021
Regeneron and Sanofi Present Results of Libtayo (cemiplimab) in P-III EMPOWER-Lung 3 Study as 1L Treatment of Advanced NSCLC at ES...
September 20, 2021
Tanvex Presents Results of TX05 (biosimilar- trastuzumab) in P-III Study for the Treatment of HER2-Positive Early Stage Breast Can...
September 20, 2021
Biocad Presents Results of BCD-021 (biosimilar- bevacizumab) in P-III Study for the Treatment of Non-Squamous Non-Small Cell Lung...
September 17, 2021
Samsung Bioepis Presents Five-year Follow-up Results of Ontruzant (biosimilar- trastuzumab) in Early or Locally Advanced HER2 Posi...
September 12, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.